share_log

Hims & Hers Health | 8-K: Hims & Hers Health, Inc. Reports Second Quarter 2024 Financial Results

Hims & Hers Health | 8-K: Hims & Hers Health, Inc. Reports Second Quarter 2024 Financial Results

Hims & Hers Health | 8-K:Hims & Hers Health, Inc. 公佈2024年第二季度財務業績
美股SEC公告 ·  2024/08/05 16:15

Moomoo AI 已提取核心訊息

Hims & Hers Health delivered exceptional Q2 2024 performance with revenue reaching $315.6 million, up 52% YoY, driven by strong subscriber growth to 1.9 million users. The company achieved significant profitability milestones with net income of $13.3 million, compared to a $7.2 million loss in Q2 2023, while Adjusted EBITDA grew to $39.3 million.The company demonstrated robust operational efficiency with gross margin at 81% and marketing expenses decreasing from 51% to 46% of revenue YoY. Free cash flow surged 377% YoY to $47.6 million, while maintaining a strong balance sheet with $227 million in cash and investments with no debt.Looking ahead, Hims & Hers raised its full-year 2024 guidance to $1.37-$1.40 billion in revenue and $140-$155 million in Adjusted EBITDA. The company also announced a new $100 million share repurchase program, reflecting confidence in its growth trajectory and commitment to delivering shareholder value.
Hims & Hers Health delivered exceptional Q2 2024 performance with revenue reaching $315.6 million, up 52% YoY, driven by strong subscriber growth to 1.9 million users. The company achieved significant profitability milestones with net income of $13.3 million, compared to a $7.2 million loss in Q2 2023, while Adjusted EBITDA grew to $39.3 million.The company demonstrated robust operational efficiency with gross margin at 81% and marketing expenses decreasing from 51% to 46% of revenue YoY. Free cash flow surged 377% YoY to $47.6 million, while maintaining a strong balance sheet with $227 million in cash and investments with no debt.Looking ahead, Hims & Hers raised its full-year 2024 guidance to $1.37-$1.40 billion in revenue and $140-$155 million in Adjusted EBITDA. The company also announced a new $100 million share repurchase program, reflecting confidence in its growth trajectory and commitment to delivering shareholder value.
Hims & HERS Health在2024年第二季度表現卓越,營業收入達到31560萬,同比增長52%,主要受益於用戶數增長至190萬。公司實現了顯著的盈利里程碑,凈利潤爲1330萬, 與2023年第二季度的720萬虧損相比,調整後的EBITDA增長至3930萬。公司展示了強大的運營效率,毛利率達到81%,營銷費用從營業收入的51%降至46%。自由現金流同比激增377%,達到4760萬,同時保持強勁的資產負債表,現金和投資總額爲22700萬,且沒有負債。展望未來,Hims & HERS將2024年全年指導上調至營業收入在13.7億至14億之間,調整後的EBITDA在140萬至15500萬之間。公司還宣佈了一項新的10000萬股份回購計劃,反映出對其增長軌跡的信任以及對股東價值的承諾。
Hims & HERS Health在2024年第二季度表現卓越,營業收入達到31560萬,同比增長52%,主要受益於用戶數增長至190萬。公司實現了顯著的盈利里程碑,凈利潤爲1330萬, 與2023年第二季度的720萬虧損相比,調整後的EBITDA增長至3930萬。公司展示了強大的運營效率,毛利率達到81%,營銷費用從營業收入的51%降至46%。自由現金流同比激增377%,達到4760萬,同時保持強勁的資產負債表,現金和投資總額爲22700萬,且沒有負債。展望未來,Hims & HERS將2024年全年指導上調至營業收入在13.7億至14億之間,調整後的EBITDA在140萬至15500萬之間。公司還宣佈了一項新的10000萬股份回購計劃,反映出對其增長軌跡的信任以及對股東價值的承諾。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息